Advertisement

Cardiovascular Drugs and Therapy

, Volume 30, Issue 6, pp 611–622 | Cite as

Risk and Benefits of Triple Therapy in Patients Undergoing Coronary Stent Implantation Requiring Oral Anticoagulation: A Meta-Analysis of 16 Studies

  • Lucia Barbieri
  • Monica Verdoia
  • Alon Schaffer
  • Harry Suryapranata
  • Giuseppe De LucaEmail author
ORIGINAL ARTICLE

Abstract

Background

Patients with coronary artery disease who undergo stent implantation and have concomitant indication for long-term oral anticoagulation represent a considerable proportion of the overall population. To date there is still no consensus about the optimal antithrombotic strategy to choose in this kind of patients, due to the difficult balance between an increased risk of bleeding and thromboembolic complications. Therefore, the aim of this study was to perform a meta-analysis to evaluate the risk and benefits of triple antithrombotic therapy versus dual antithrombotic therapy in patients undergoing coronary stent implantation, requiring long-term oral anticoagulation.

Methods

We performed formal searches of PubMed, EMBASE, Cochrane central register of controlled trials and major international scientific session abstracts from January 1990 to September 2015 regarding the use of triple antithrombotic therapy (TT) versus dual therapy (DT) in patients undergoing percutaneous coronary stent implantation that required chronic oral anticoagulation. Data regarding study design, inclusion/exclusion criteria, number of patients, and selected endpoints was extracted by 2 investigators. Disagreements were resolved by consensus.

Results

Sixteen trials with a total of 21716 patients undergoing coronary stent implantation with indication to long term oral anticoagulation, were finally included. A total of 6950 received TT, whereas 14766 received DT alone. The follow-up period ranged from 180 to 730 days. Data regarding mortality were available in 21658 patients (99.7 %). All cause mortality was observed in 10.4 % patients in TT versus 16.3 % in DT (OR [95 % CI] =0.73 [0.66–0.80], p <0.001; p het <0.001). In addition, TT was associated with a reduced incidence of MI (6.4 versus 9.8 %, OR [95 % CI] = 0.74 [0.65–0.84], p < 0.001; phet < 0.001) and ischemic stroke (1.8 versus 3.9 %, OR [95 % CI] = 0.55 [0.45–0.68], p < 0.001; p het  = 0.07). As expected, TT was associated with a significant increase in major bleeding events (10.8 versus 8.5 %, OR [95 % CI] = 1.38 [1.25–1.53], p < 0.001; p het  = 0.02). By meta regression analysis we found that benefits in mortality with TT were inversely related with the risk of bleedings (beta [95 % CI] = 2.25 (1.55; 2.95), p < 0.00001). The benefits with TT regarding overall mortality, recurrent MI and ischemic stroke were also confirmed in a pre-specified analysis versus DAPT or oral anticoagulation in association with a single antiplatelet agent.

Conclusion

This meta-analysis showed that among patients undergoing coronary stent implantation, requiring chronic OAC, the use of a TT is associated with a significant reduction in overall mortality, recurrent MI and ischemic stroke. As expected, we found a higher incidence of bleedings in patients treated with triple therapy. The benefits in mortality were lost in patients at high-risk for bleedings.

Keywords

Triple therapy Thromboembolic complications Bleedings 

Notes

Acknowledgments

Prof De Luca had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Compliance with Ethical Standards

Conflict of Interest

The authors have no conflict of interest regarding the opinion expressed in this manuscript and did not receive grant or financial support from industry or from any other source to prepare this review.

References

  1. 1.
    Stone GW, Witzenbichler B, Guagliumi G, et al. HORIZONS-AMI trial investigators. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet. 2011;377:2193–204.CrossRefPubMedGoogle Scholar
  2. 2.
    Navarese EP, De Luca G, Castriota F, et al. Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis. Thromb Haemost. 2011;9:1902–15.CrossRefGoogle Scholar
  3. 3.
    De Luca G, Dirksen MT, Spaulding C, et al. Drug-eluting stent in primary angioplasty (DESERT) cooperation. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Arch Intern Med. 2012;172:611–21.PubMedGoogle Scholar
  4. 4.
    Capozzolo C, Piscione F, De Luca G, et al. Direct coronary stenting: effect on coronary blood flow, immediate and late clinical results. Catheter Cardiovasc Interv. 2001;53:464–73.CrossRefPubMedGoogle Scholar
  5. 5.
    De Luca G, Navarese EP, Suryapranata H, et al. A meta-analytic overview of thrombectomy during primary angioplasty. Int J Cardiol. 2013;166:606–12.CrossRefPubMedGoogle Scholar
  6. 6.
    Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2014;35:2541–619.CrossRefPubMedGoogle Scholar
  7. 7.
    Fuster V, Ryden LE, Cannom DS. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: A report of the american college of cardiology/ american heart association task force on practice guidelines and the european society of cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). Eur Heart J. 2006;27:1979–2030.CrossRefPubMedGoogle Scholar
  8. 8.
    The ACTIVE writing group on behalf of the ACTIVE investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE W): a randomized controlled trial. Lancet. 2006;367:1903–012.CrossRefGoogle Scholar
  9. 9.
    De Luca G, Dirksen MT, Spaulding C. Time course, predictors and clinical implications of stent thrombosis following primary angioplasty. Insights from the DESERT cooperation. Thromb Haemost. 2013;110:826–33.CrossRefPubMedGoogle Scholar
  10. 10.
    Maegdefessel L, Schlitt A, Faerber J, et al. Anticoagulant and/or antiplatelet treatment in patients with atrial fibrillation after percutaneous coronary intervention. Med Klin. 2008;103:628–32.CrossRefGoogle Scholar
  11. 11.
    ACC/AHA/SCAI. 2005 guideline update for percutaneous coronary intervention summary article: a report of the American college of cardiology/American heart association task force on practice guidelines (ACC/AHA/SCAI writing committee to update the 2001 guidelines for percutaneous coronary intervention). Circulation. 2006;113:156–75.CrossRefGoogle Scholar
  12. 12.
    Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions: the task force for percutaneous coronary interventions of the European society of cardiology. Eur Heart J. 2005;26:804–47.CrossRefPubMedGoogle Scholar
  13. 13.
    De Luca G, Schaffer A, Wirianta J, Suryapranata H. Comprehensive meta-analysis of radial vs femoral approach in primary angioplasty for STEMI. Int J Cardiol. 2013;168:2070–81.CrossRefPubMedGoogle Scholar
  14. 14.
    Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151:W65–94.CrossRefPubMedGoogle Scholar
  15. 15.
    Fosbol E, Wang TY, Li S, et al. Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction. Am Heart J. 2012;163:720–8.CrossRefPubMedGoogle Scholar
  16. 16.
    GaoF ZYJ, Wang ZJ, et al. Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation. Circ J. 2010;74:701–8.CrossRefGoogle Scholar
  17. 17.
    Gilard M, Blanchard D, Helft G, et al. Antiplatetlet therapy in patients with anticoagulants undergoing percutaneous coronary stenting (from STENTIng and oral antiCOagulants-STENTICO). Am J Cardiol. 2009;104:338–42.CrossRefPubMedGoogle Scholar
  18. 18.
    Fiedler KA, Maeng M, Mehilli J, et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation (ISAR-TRIPLE Trial). TCT. 2014.Google Scholar
  19. 19.
    Karjalainen PP, Porela P, Ylitalo A, et al. Safety and efficacy of combinet antiplatelet-warfarin therapy after coronary stenting. Eur Heart J. 2007;28:726–32.CrossRefPubMedGoogle Scholar
  20. 20.
    Manzano-Fernandez S, Pastor FJ, Marin F, et al. Increase major bleeding complication related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting. CHEST. 2008;134:559–67.CrossRefPubMedGoogle Scholar
  21. 21.
    Mattichak SJ, Reed PS, Gallagher MJ, et al. Evaluation of safety of Warfarin in combination with antiplatelet therapy for patients treated with coronary stent for acute myocardial infarction. J Interven Cardiol. 2005;18:163–6.CrossRefGoogle Scholar
  22. 22.
    Rubboli A, Magnavacchi P, Guastaroba P, et al. Antithrombotic menagement and 1 year outcome of patients on oral anticoagulation undergoing coronary stent implantation (from the Registro regionale Angioplastiche Emilia-Romagna registry). Am J Cardiol. 2012;109:1411–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Sarafoff G, Ndrepepa G, Mehilli J, et al. Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation. J Int Med. 2008;264:472–80.CrossRefGoogle Scholar
  24. 24.
    Dewilde WM, Oirbans T, Verheugt FWA, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open label, randomised, controlled trial. Lancet. 2013;381:1107–15.CrossRefPubMedGoogle Scholar
  25. 25.
    Hess CN, Peterson ED, Peng SA, et al. Use and outcomes of triple therapy among older patients with acute myocardial infarction and atrial fibrillation. J Am Coll Cardiol. 2015;66:616–27.CrossRefPubMedGoogle Scholar
  26. 26.
    Nguyen MC, Lim YL, Walton A, et al. Combining warfarin and antiplatelet therapy after coronary stenting in the global registry of acute coronary events: is it safe and effective to use just one antiplatelet agent? EHJ. 2007;1717–1722.Google Scholar
  27. 27.
    Sambola A, Ferreira-Gonzàlez I, Angel J, et al. Therapeutic strategies after coronary stenting in chronically anticoagulated patients: the MUSICA study. Heart. 2009;95:1483–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Ho KW, Ivanov J, Freixa X, et al. Antithrombotic therapy after coronary stenting in patients with non valvular atrial fibrillation. Can J Cardiol. 2013;29:213–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Lamberts M, Gislason GH, Olesen JB, et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol. 2013;62:981–9.CrossRefPubMedGoogle Scholar
  30. 30.
    De Luca G, Smit JJ, Ernst N, et al. Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. Thromb Haemost. 2005;93:820–3.PubMedGoogle Scholar
  31. 31.
    De Luca G, Verdoia M, Suryapranata H. Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials. Atherosclerosis. 2012;222:426–33.CrossRefPubMedGoogle Scholar
  32. 32.
    Navarese EP, Kubica J, Castriota F, et al. Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials. EuroIntervention. 2011;7:985–94.CrossRefPubMedGoogle Scholar
  33. 33.
    Khurram Z, Chou E, Minutello RJ, et al. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. Invasive Cardiol. 2006;18:162–4.Google Scholar
  34. 34.
    Konstantino Y, Iakobishvili Z, Porter A, et al. Aspirin, warfarin and a thienopyridine for acute coronary syndromes. Cardiology. 2006;105:80–5.CrossRefPubMedGoogle Scholar
  35. 35.
    Porter A, Konstantino Y, Iakobishvili Z, et al. Short-term triple therapy with aspirin, warfarin, and a thienopyridine among patients undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2006;68:56–61.CrossRefPubMedGoogle Scholar
  36. 36.
    D’Ascenzo F, Taha S, Moretti C, et al. Meta analysis of randomized controlled trias and adjusted observational results of use of clopidogrel, aspirin, and oral anticoagulants in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2015;115:1185–993.CrossRefPubMedGoogle Scholar
  37. 37.
    Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation. 2007;115:e69–171.CrossRefPubMedGoogle Scholar
  38. 38.
    Chen CF, Chen B, Zhu J, Xu YZ. Antithrombotic therapy after percutaneous coronary intervention in patients requiring oral anticoagulant treatment. Herz. 2015;40:1070–83.CrossRefPubMedGoogle Scholar
  39. 39.
    Suryapranata H, De Luca G. Short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO™ dual-therapy stent: what we plan to learn from REDUCE. Futur Cardiol. 2015;11:17–20.CrossRefGoogle Scholar
  40. 40.
    A Randomized Clinical Evaluation of the BioFreedonTM Stent (Leaders Free). https://clinicaltrials.gov/ct2/show/NCT01623180?term=BIOFREEDOM&rank=4
  41. 41.
    Global Leaders: a clinical study comparing two forms of anti-platelet therapy after stent Implantation. https://clinicaltrials.gov/ct2/show/NCT01813435?term=Global+Leaders&rank=1

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Lucia Barbieri
    • 1
  • Monica Verdoia
    • 1
  • Alon Schaffer
    • 1
  • Harry Suryapranata
    • 2
  • Giuseppe De Luca
    • 1
    Email author
  1. 1.Division of Cardiology, Azienda Ospedaliera-Universitaria “Maggiore della Carità”Eastern Piedmont UniversityNovaraItaly
  2. 2.Department of CardiologyUMC St RadboudNijmegenThe Netherlands

Personalised recommendations